C-X-C chemokine receptor type 5+CD8+T cells as immune regulators in hepatitis Be antigen-positive chronic hepatitis B under interferonalpha treatment  

作　　者：Zhen-Yu Xu Zhong-Shang Dai Guo-Zhong Gong Min Zhang 

机构地区：[1]Department of Infectious Diseases,Second Xiangya Hospital,Central South University,Changsha 410011,Hunan Province,China [2]Institute of Hepatology and Department of Infectious Diseases,The Second Xiangya Hospital,Central South University,Changsha 410011,Hunan Province,China

出　　处：《World Journal of Gastroenterology》2025年第3期73-83,共11页世界胃肠病学杂志（英文）

基　　金：Supported by Changsha Science and Technology Program,No.kq2022397;Natural Science Foundation of Hunan Province(Departmental Joint Fund),No.2023JJ60440;Research Program of Health Commission of Hunan Province,No.202303088786;Clinical Medical Research Center for Viral Hepatitis of Hunan Province,No.2023SK4009;the Scientific Research Program of FuRong Laboratory,No.2023SK2108.

摘　　要：BACKGROUND C-X-C chemokine receptor type 5(CXCR5)^(+)CD8^(+)T cells represent a unique immune subset with dual roles,functioning as cytotoxic cells in persistent viral infections while promoting B cell responses.Despite their importance,the specific role of CXCR5^(+)CD8^(+)T cells in chronic hepatitis B(CHB),particularly during interferon-alpha(IFN-α)treatment,is not fully understood.This study aims to elucidate the relationship between CXCR5^(+)CD8^(+)T cells and sustained serologic response(SR)in patients undergoing 48 weeks of pegylated IFN-α(peg-IFN-α)treatment for CHB.AIM To elucidate the relationship between CXCR5^(+)CD8^(+)T cells and sustained SR in patients undergoing 48 weeks of peg-IFN-αtreatment for CHB.METHODS This study enrolled 60 patients with hepatitis Be antigen(HBeAg)-positive CHB undergoing 48 weeks of peg-IFN-αtreatment.Participants were assessed for eligibility based on criteria such as persistent HBsAg-positive status for at least six months,HBeAb-negative,hepatitis B virus DNA levels exceeding 2×10^(4) copies/mL,and alanine aminotransferase(ALT)levels between 2 and 10 times the upper limit of normal.Blood samples were collected at baseline and at weeks 12,24,48,and a 24-week treatment-free follow-up(week 72)to measure serum interleukin(IL)-21 concentration via ELISA and to analyze CXCR5 and programmed death-ligand 1(PD-L1)expression on CD8^(+)T cells by flow cytometry,CXCR5 is a chemokine receptor that directs immune cells to specific tissues,while PD-L1 is a protein that regulates immune responses by inhibiting T cell activity.RESULTS Patients with CHB exhibited significantly lower levels of circulating CXCR5^(+)CD8^(+)T cells compared to healthy controls(P<0.01).Notably,CXCR5^(+)CD8^(+)T cells were prominently expressed in patients who achieved sustained SR compared to non-SR(NSR).A significant correlation was observed between CXCR5 and PD-L1 expression(r=-0.189,P=0.002).However,there was no significant correlation between serum IL-21 levels and CXCR5+CD8+lymphocytes(r=-0.03,P=0.62

关 键 词：C-X-C chemokine receptor type 5 Programmed death-ligand 1 INTERLEUKIN-21 Pegylated interferon-alpha Chronic hepatitis B 

分 类 号：R512.62[医药卫生—内科学]